Hyatt Hotels Corporation enters the final trading days of August with a striking divergence at its core: short sellers have been quietly rebuilding positions all month, yet options traders are the most bullish they have been all year.
The short interest story has been grinding higher without fanfare. At 12% of the free float, Hyatt's short position is already elevated for a major hotel operator. More telling is the pace — SI has risen roughly 12% over the past month and added nearly 4% in the past week alone. The stock itself has dropped 9% over the past month to $172.25, and fell close to 5% this week. Short sellers are adding into weakness, not chasing a reversal.
The borrow market tells a sharply different story from the options desk, and the divergence is the most interesting tension in this setup right now. Availability has tightened meaningfully — from above 180% in late July to 63% now, the fastest compression in the past six weeks. That is still within the "tight" range rather than extreme, and cost to borrow remains low at 0.84%. Borrow costs have risen 44% over the past month but from a very low base. There is no squeeze pressure building yet, just a clear and accelerating shift: more of the lending pool is being absorbed. The ORTEX short score has climbed to 72.4, a new recent high, and has moved up every single session this week.
Options positioning is a clean counterpoint. Call volume has surged relative to puts — the put/call ratio hit 0.155 on Friday, nearly 1.4 standard deviations below its 20-day average of 0.36, and close to the lowest reading of the past year. That reading is the opposite of the defensive hedging you might expect given the stock's slide. Options traders are either positioning for a bounce or expressing conviction that the selloff has been overdone. The two camps — shorts rebuilding, options buyers leaning bullish — are pulling in opposite directions.
Analysts have been cutting numbers without abandoning ratings. Morgan Stanley trimmed its target to $209 from $218 on August 18 while keeping Overweight. JPMorgan did the same a week earlier, lowering to $209 from $215, also Overweight. Barclays went further, cutting to $201 from $220 — still Overweight. The pattern is consistent: positive ratings, lower targets. The consensus mean sits at $196, roughly 14% above the current price. The bull case rests on a 141,000-room development pipeline growing at 4.4% year-on-year and strong Asia-Pacific RevPAR, while bears point to downward EBITDA revisions — 2026 estimates cut to $1.18B — and a PE multiple still above 39x that leaves limited cushion if growth disappoints. The analyst recommendation factor scores in the 94th percentile, suggesting the Street's directional tilt remains positive even as targets move lower.
Insider flows add a note of caution. CEO Mark Hoplamazian sold roughly $20 million of stock in mid-to-late June at prices around $195-205 — well above where the stock trades now. The CFO followed with a smaller sale in early August. Net insider activity over the past 90 days registers as selling. This was not distress selling — the prices were near recent highs — but executives were clearly not adding at those levels.
The next earnings date is October 29. The most recent print on July 30 saw the stock fall 6.4% on the day and give back a further 3.8% over the following week — a pattern worth tracking as short interest continues to build into that event and options traders position for recovery.
See the live data behind this article on ORTEX.
Open H on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
